Global Pediatric Drugs and Vaccines Market Research Report 2022

Children differ from adults in many aspects of pharmacotherapy, including capabilities for drug administration, medicine-related toxicity, and taste preferences. It is essential that pediatric medicines are formulated to best suit a child's age, size, physiologic condition, and treatment requirements. Therefore, the pediatric drug and vasccines specially serve for children.
Due to the COVID-19 pandemic, the global Pediatric Drugs and Vaccines market size is estimated to be worth US$ 95480 million in 2021 and is forecast to a readjusted size of US$ 176440 million by 2028 with a CAGR of 9.0% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Pediatric Drugs and Vaccines market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Pediatric Drugs and Vaccines landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Diphtheria accounting for % of the Pediatric Drugs and Vaccines global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Newborn segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Pediatric Drugs and Vaccines include Merck & Co., Inc. (USA), Abbott Laboratories (USA), Amgen, Inc. (USA), Eli Lilly and Company (USA), F. Hoffmann-La Roche Ltd (Switzerland), Genentech, Inc. (USA), GlaxoSmithKline plc. (UK), Janssen Biologics B.V. (USA) and Actelion Pharmaceuticals, etc. In terms of revenue, the global 3 largest players have a % market share of Pediatric Drugs and Vaccines in 2021.
This report focuses on Pediatric Drugs and Vaccines volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Pediatric Drugs and Vaccines market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Pediatric Drugs and Vaccines Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Diphtheria
Influenza
Hepatitis
Pneumococcal Diseases
Meningococcal Diseases
Mumps
Others
Segment by Application
Newborn
Infant
Child
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Merck & Co., Inc. (USA)
Abbott Laboratories (USA)
Amgen, Inc. (USA)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd (Switzerland)
Genentech, Inc. (USA)
GlaxoSmithKline plc. (UK)
Janssen Biologics B.V. (USA)
Actelion Pharmaceuticals
AstraZeneca Plc. (UK)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Allergan, Inc. (USA)
Novartis AG (Switzerland)
Novo Nordisk A/S (Denmark)
Pfizer, Inc. (USA)
Sanofi S.A (France)
Shionogi Inc. (USA)
Takeda